Are you the publisher? Claim or contact us about this channel


Embed this content in your HTML

Search

Report adult content:

click to rate:

Account: (login)

More Channels


Showcase


Channel Catalog


Channel Description:

Visit One News Page for Europe news from around the world, aggregated from leading sources including newswires, newspapers and broadcast media. Search millions of archived news headlines. This feed provides the Europe news headlines.

older | 1 | .... | 1565 | 1566 | (Page 1567) | 1568 | 1569 | .... | 1652 | newer

    0 0

    Rivian's R1S SUV is based on a modular 'skateboard'-style architecture...

    American start-up's third model to exploit performance value of universal 'skateboard' architecture

    The third model to come from new start-up electric car maker Rivian will be a rally-raid style performance car.

    Speaking to Autocar at the LA motor show, Rivian founder and CEO RJ Scaringe said that the model to follow its initial R1T pick-up truck and R1S SUV would be “bananas” in the way it performed.

    “The third vehicle will have a smaller wheelbase [than the R1S SUV] and will be the Rivian interpretation of a rally car with a lot of ground clearance,” said Scaringe.

    Any car Rivian makes has a “combination of on and off-road performance, and a level of functionality that’s unique in its space”, according to Scaringe.

    The UK is very much in Rivian’s plans for its models, with 2021 a likely launch date here for its initial offerings in right-hand drive. Construction will take place in a former Mitsubishi plant that’s currently being converted to Rivian’s requirements, with plenty of the existing infrastructure and machinery able to be used.  

    *Electric start-up Rivian unveils R1S SUV and R1T pick-up to rival Tesla*

    Rivian also has plans to offer its modular skateboard chassis to other car makers, so long as its products don’t compete. Scaringe said he had had several approaches from interested car makers already, and also some from non-car makers interested in launching into the automotive world on a ready-made architecture. 

    The electric skateboard chassis allows for all different types of vehicle to be spawned from it, from cars to public transport. “You could build an 800hp R1T truck or a goods delivery van, or a shuttle bus,” said Scaringe. It’s this that could bring other non-automotive players into the industry, such as online retailers launching their own delivery vehicles. 

    The appeal for car makers is that new architectures are very expensive to develop, and Rivian now has an infinitely flexible one available off the shelf, and can even build the car so long as it does not compete with its own offerings.

    To that end, Rivian plans to keep its own-brand products to smaller, more limited volumes, to stop the brand being too diluted and trying to appeal to a wider customer base.

    Rivian is planning a full global launch for its models, including in both left- and right-hand drive. “California is a huge market here,” said Scaringe. “But China, Europe, North America too, and in right-hand drive [for UK] – in Australia, South Africa.

    “I’ve had lots of requests in the past 24 hours, it’s been a united nations of countries.”

    Rivian plans to sell direct to the consumer where it can, but will partner with dealers in places where that doesn’t allow.

    “We’ll offer direct sale in a lot of areas where possible,” said Scaringe. “In some markets and states [where it isn’t possible] we’ll have partners. Then we’ll have partners on back-end things like servicing. We will own the customer service and experience – it’s important to own that. Dealers understand how to manage scale and how to add value on servicing and parts.”

    *Read more*

    *Why Rivian isn't just another electric start-up*

    *2018 Los Angeles motor show: all the news and pictures​*

    *New Kia Soul EV revealed at LA show with more power and range​* Reported by Autocar 1 hour ago.

    0 0

    EQS Group-News: ADC Therapeutics SA / Key word(s): Conference

    05.12.2018 / 07:00
    --------------------

    *ADC Therapeutics Presents Updated Data from Clinical Trials of Novel Antibody Drug Conjugates*
     

    ADCT-402 (loncastuximab tesirine) continues to demonstrate acceptable safety profile and anti-tumor activity in patients with relapsed or refractory diffuse large B-cell lymphoma; data from 183-patient study supports continued evaluation in ongoing pivotal Phase II trial

    ADCT-301 (camidanlumab tesirine) achieves 86.5 percent overall response rate in heavily pretreated patients with Hodgkin lymphoma; data from 113-patient study supports further investigation in pivotal Phase II trial

    Data presented at 60^th American Society of Hematology (ASH) Annual Meeting

    *Lausanne, Switzerland, December 5, 2018* - ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), presented updated data from ongoing Phase I clinical trials of ADCT-402 (loncastuximab tesirine) and ADCT-301 (camidanlumab tesirine) in multiple subtypes of lymphoma during oral and poster presentations at the 60^th American Society of Hematology (ASH) Annual Meeting in San Diego.

    "We are encouraged by the safety profiles and strong single-agent anti-tumor activity we continue to observe in the 183-patient first-in-human clinical trial of ADCT-402 and the 113-patient trial of ADCT-301," said Jay Feingold, MD, PhD, Chief Medical Officer and Senior Vice President of Clinical Development at ADC Therapeutics. "The updated ADCT-402 data presented at ASH support its continued evaluation in our ongoing pivotal clinical trial in patients with relapsed or refractory diffuse large B-cell lymphoma. For ADCT-301, we now have the dosing data to support further investigation in a planned pivotal Phase II trial in patients with relapsed or refractory Hodgkin lymphoma, which we look forward to initiating in 2019."

    *ADCT-402 Oral and Poster Presentations at ASH*

    *Interim Results from the First-in-Human Clinical Trial of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma* (Abstract 398)
    Oral presentation: John Radford, MD, FRCP, Manchester Academic Health Centre, The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK

    Data were presented from a subpopulation of 139 evaluable patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who had failed or were intolerant to established therapies. The patients had a median age of 63 years and had received a median of three previous therapies. Patients received doses of ADCT-402 ranging from 15 to 200 µg/kg every three weeks. The median number of cycles received was two and the median duration of treatment was 43 days.

    Key findings from the oral presentation include:

    - ADCT-402 has demonstrated manageable toxicity in patients with R/R DLBCL

    - At doses >120 µg/kg, the overall response rate (ORR) was 43.3% (55/127 patients with DLBCL), comprising 23.6% complete responses and 19.7% partial responses

    - At doses >120 µg/kg, after a median follow up of 5.5 months, median duration of response (DoR) was not reached in patients achieving a complete response

    A pivotal Phase II study is currently enrolling patients with R/R DLBCL to evaluate the efficacy and safety of ADCT-402 at dose 150 µg/kg every three weeks for two cycles followed by dose 75 µg/kg every three weeks (NCT03589469).

    *Safety and Efficacy of ADCT-402 (Loncastuximab Tesirine), a Novel Antibody Drug Conjugate, in Relapsed/Refractory Follicular Lymphoma and Mantle Cell Lymphoma: Interim Results from the Phase I First-in-Human Study *(Abstract 2874)
    Poster presentation: Paolo Caimi, MD, Case Western Reserve University, University Hospitals Cleveland Medical Center, Cleveland, OH

    Data were presented from a subgroup of 29 patients, including 14 patients with follicular lymphoma (FL) and 15 patients with mantle cell lymphoma (MCL). The median age of the FL patients was 60.5 years and the median age of the MCL patients was 64 years. Patients received infusions every three weeks at doses ranging from 15 to 200 µg/kg. Patients with FL and MCL received a median of three and two cycles of ADCT-402, respectively.

    Key findings from the poster presentation include:

    - ADCT-402 has demonstrated manageable toxicity in patients with R/R FL and R/R MCL

    - In patients with FL, ORR was 78.6% (11/14) and median DoR was not reached after a median follow-up time of 11.6 months

    - In patients with MCL, ORR was 46.7% (7/15) and median DoR was not reached after a median follow-up time of 8.7 months*ADCT-301 Oral and Poster Presentations at ASH

    Phase I Study of ADCT-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma* (Abstract 928)
    Oral presentation: Mehdi Hamadani, MD, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

    Data were presented from 67 evaluable, heavily pretreated patients with relapsed/refractory (R/R) classical Hodgkin Lymphoma (HL) who had failed or were intolerant to any established therapy known to provide clinical benefit. The median age of the patients was 38 years and they had received a median of five prior therapies. Patients were treated with doses of ADCT-301 ranging from 5 to 300 µg/kg. They completed a median of three cycles of treatment and median treatment duration was 43 days.

    Key findings from the oral presentation include:

    - ADCT-301 has demonstrated manageable toxicity in patients with R/R HL

    - The most common Grade 3 or 4 treatment-emergent adverse events occurring in at least 5 percent of patients, regardless of attribution, at the 45 µg/kg dose in 37 patients were: maculopapular rash (18.9 percent),elevated gamma-glutamyltransferase (8.1 percent), elevated alanine aminotransferase (8.1 percent), elevated aspartate aminotransferase (2.7 percent), anemia (8.1 percent), Guillain-Barré syndrome / radiculopathy (8.1 percent) and increased lipase (8.1 percent)

    - In patients with R/R HL, therapy with ADCT-301 achieved an overall response rate (ORR) of 86.5% in the 37 patients in the 45 µg/kg dose group who had received and failed prior brentuximab vedotin and most of whom had failed prior checkpoint inhibitor treatment

    - These data support further investigation of the 45 µg/kg dose of ADCT-301 in a planned pivotal Phase II study anticipated to commence in 2019*ADCT-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based CD25-Targeting Antibody Drug Conjugate, in a Phase I Study of Relapsed/Refractory Non-Hodgkin Lymphoma Shows Activity in T-Cell Lymphoma *(Abstract 1658)
    Poster presentation: Graham P. Collins, MB, BS, DPhil, Oxford University Hospitals, NHS Trust, Oxford, UK

    Data were presented from 44 patients with R/R non-Hodgkin lymphoma (NHL) with a median age of 65.5 years who had received a median number of four previous systemic therapies (including prior stem cell transplant). Of those, 22 patients were in a T-cell lymphoma subgroup. Patients were treated with doses of ADCT-301 ranging from 3 to 150 µg/kg and received a median number of two cycles. Median treatment duration was 22 days.

    Key findings from the poster presentation include:

    - ADCT-301 demonstrated an acceptable safety profile during dose-escalation

    - Overall, in patients with R/R NHL, therapy with ADCT-301 achieved an ORR of 31.7% (13/41) at doses >60 µg/kg

    - In the R/R T-cell lymphoma subgroup, therapy with ADCT-301 achieved an ORR of 53.8% (7/13) in the 60 and 80 µg/kg dose groups

    - These data support further investigation of ADCT-301 in T-cell lymphoma*About ADCT-402*

    ADCT-402 (loncastuximab tesirine) is an antibody drug conjugate (ADC) composed of a humanized monoclonal antibody that binds to human CD19, conjugated through a linker to a pyrrolobenzodiazepine (PBD) dimer toxin. Once bound to a CD19-expressing cell, ADCT-402 is internalized into the cell where enzymes release the PBD-based warhead. CD19 is a clinically validated target for the treatment of B-cell malignancies. The PBD-based warhead has the ability to form highly cytotoxic DNA interstrand cross-links, blocking cell division and resulting in cell death. ADCT-402 is being evaluated in a pivotal Phase II clinical trial in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (NCT03589469). The U.S. Food and Drug Administration granted orphan drug designation to ADCT-402 for the treatment of DLBCL and mantle cell lymphoma.

    *About ADCT-301*

    ADCT-301 (camidanlumab tesirine) is an antibody drug conjugate (ADC) composed of a monoclonal antibody that binds to CD25 (HuMax(R)-TAC, licensed from Genmab A/S), conjugated to the pyrrolobenzodiazepine (PBD) dimer payload tesirine. Once bound to a CD25-expressing cell, ADCT-301 is internalized into the cell where enzymes release the PBD-based warhead. The intra-tumor release of its PBD warhead may cause bystander killing of neighboring tumor cells. In addition, the PBD warhead will trigger immunogenic cell death, which in turn will strengthen the immune response against tumor cells. ADCT-301 is being evaluated in ongoing Phase Ia/Ib clinical trials in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma (NCT02432235), as well as a Phase Ib clinical trial in solid tumors (NCT03621982).

    *About ADC Therapeutics*
    ADC Therapeutics SA is an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs) targeting major hematological malignancies and solid tumors. The Company's ADCs are highly targeted biopharmaceutical drugs that combine monoclonal antibodies specific to surface antigens present on particular tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads via a chemical linker. The Company has multiple PBD-based ADCs in ongoing clinical trials in the USA and Europe, and a deep pipeline of other preclinical ADCs in development. ADC Therapeutics has world-class partners, including AstraZeneca and its global biologics research and development arm, MedImmune. The Company is based in Lausanne (Biopôle), Switzerland and has operations in London, San Francisco and New Jersey. For more information, visit www.adctherapeutics.com.*Investors Contact *
    Dr. Chris Martin
    Chief Executive Officer
    Chris.martin@adctherapeutics.com
    Tel: +41 (0) 21 653 0200

    *EU Media Contact *
    Alexandre Müller
    Dynamics Group
    amu@dynamicsgroup.ch
    Tel: +41 (0) 43 268 3231

    *USA Media Contact*
    Tony Plohoros
    6 Degrees
    tplohoros@6degreespr.com
    Tel: +1 908-591-2839

    --------------------
    Additional features:

    Document: http://n.eqs.com/c/fncls.ssp?u=NCVOSLAFND
    Document title: ADCT_ASH 2018 Data_5.12.2018 --------------------

    End of Corporate News -------------------- Reported by EQS Group 1 hour ago.

    0 0

    The United States delivered Russia a 60-day ultimatum on Tuesday (4 December) to come clean about what Washington says is a violation of a arms control treaty that keeps missiles out of Europe, saying only Moscow could save the pact. Reported by EurActiv 1 hour ago.

    0 0

    Reported by FT.com 1 hour ago.

    0 0

    TOKYO, Dec 5, 2018 - (JCN Newswire) - Mitsubishi Corporation (MC), through its wholly-owned subsidiary Diamond Transmission Corporation (DTC), has been selected as the preferred bidder for a new, offshore electricity transmission link in the UK. This marks the seventh electricity transmission project for MC in the UK. The new offshore electricity transmission asset connects the Galloper Offshore Windfarm (generation capacity of 353MW), situated approximately 30 km off the country's eastern coast, with the Sizewell substation. The transmission line is composed of subsea and land cables and offshore and onshore substations, and is valued at GBP 329.1 million.

    MC will execute this electricity transmission business for a 20-year period starting around the second quarter of 2019, following successful acquisition of the asset and the granting of an Offshore Transmission Owner (OFTO) license by the UK's Office of Gas and Electricity Markets (Ofgem).

    With the acquisition of the Galloper Offshore Windfarm transmission link, DTC will now be operating seven offshore transmission assets in the UK, which is the largest share considering that there is a total of 19 assets across the country. Combined with four others held in Germany, the number of power transmission assets held by DTC in Europe will add up to eleven, for a gross transmission length of approximately 1,000 km and an electricity transmission capacity of around 5.3 GW.

    DTC is seeking to expand its independent management functions and deepen its commitments in the offshore transmission business by leveraging the skills of its highly qualified in-house team of technical and accounting specialists.

    A European Commission roadmap suggests the EU is aiming to cut its greenhouse gas emissions to 80% of 1990 levels by 2050. In line with that target, the EU expects to generate some 50 GW of offshore wind power capacity by 2030. The availability of stably operated undersea cable transmission systems that connect offshore wind power generation plants to onland power grids is increasingly critical in that context. For its part, MC sees its participation in offshore transmission and other businesses that contribute to reducing greenhouse emissions as an opportunity to realize its vision of simultaneously generating economic, societal and environmental value through its businesses.

    About Mitsubishi Corporation

    Mitsubishi Corporation, headquartered in Tokyo, is a global integrated business enterprise that develops and operates business across virtually every industry including industrial finance, energy, metals, machinery, chemicals, foods, and environmental business. Mitsubishi Corporation's current activities are expanding far beyond its traditional trading operations as its diverse business ranges from natural resources development to investment in retail business, infrastructure, financial products and manufacturing of industrial goods. For more information on Mitsubishi Corporation, please visit the company's website at https://www.mitsubishicorp.com/jp/en/.
    Contact:
    Mitsubishi Corporation
    Telephone: +81-3-3210-2171
    Facsimile: +81-3-5252-7705Copyright 2018 JCN Newswire. All rights reserved. www.jcnnewswire.com Reported by ACN Newswire 1 hour ago.

    0 0

    According to the report, the global cochlear implants market was valued at approximately USD 1.4 billion in 2017 and is expected to generate revenue of around USD 2.6 billion by the end of 2024, growing at a CAGR of around 9.6% between 2018 and 2024.

    New York, NY, Dec. 05, 2018 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled *“Cochlear Implants Market by Type (Unilateral and Binaural) by Application (Children and Adult): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017 – 2024”*. According to the report, the global cochlear implants market was valued at approximately USD 1.4 billion in 2017 and is expected to generate revenue of around USD 2.6 billion by the end of 2024, growing at a CAGR of around 9.6% between 2018 and 2024. 

    A cochlear implant is a medical device that converts sound into electrical signals and restores the sense of hearing by performing the work of damaged parts of the cochlea by transmitting the electrical signals to the brain. It is used by people with low to high hearing loss due to various reasons. These cochlear implants are surgically implanted and consist of two parts. The inside component is implanted across the skin while the other external component is worn at the back of the ear. Cochlear implants convert sound into electrical signals and stimulate the auditory nerve and interpret them as speech or sound. The cochlear implants bypass the non-functioning part of the inner ear and provide electrical stimulation to the nerve fibers present in the cochlea. The surgical procedure for implantation is performed under general anesthesia with minimal risk.

    *Browse through 54 Tables & 12 Figures spread over 110 Pages and in-depth TOC on “Global Cochlear Implants Market Size 2017 Report: Industry Type, Share, Growth, Segments, Analysis and Forecast to 2024”.*

    *Request Free Sample Report of Global Cochlear Implants Market Report @ *https://www.zionmarketresearch.com/sample/cochlear-implants-market

    Cochlear implants market growth in the forecast timeframe is driven by various factors, such as increased prevalence of hearing loss coupled with an increase in the geriatric population. As per the Hearing Health Foundation Report, there were around 360 million people living with hearing loss globally. Furthermore, increasing geriatric population is also a major factor contributing to the development of cochlear implants market in the forecast timeframe Moreover, technological advancements made in cochlear implants has led to the launch and approvals of various cochlear implants with new features. This is further anticipated to promote the development of this market. Furthermore, an increase in the number of infants born with hearing defects coupled with the increased demand for customization, appearance, and concealing of these devices are also anticipated to support the growth of the cochlear implants market in the forecast timeline. However, the high costs of cochlear implants and implant procedure might hamper the global cochlear implants market during the estimated timeframe.

    The cochlear implants market is classified into type and application. Based on the type, the cochlear implant market is divided into unilateral and binaural. The binaural segment is anticipated to dominate the cochlear implant market in the forecast timeframe. Based on application, the cochlear implants market is bifurcated into adult and children. Children segment is projected to dominate the cochlear implants market in the forecast timeframe.

    *Download Free Report PDF Brochure: *https://www.zionmarketresearch.com/requestbrochure/cochlear-implants-market

    Europe is anticipated to dominate the cochlear implants market in the forecast timeframe, owing to the presence of advanced technology coupled with research and development activities undertaken by major firms to develop and launch new products. Moreover, developed economies have modern healthcare facilities as compared to other regions which will further promote the growth of the cochlear implants market in the near future across the region.

    North America is set to be the second largest growing region over the forecast period, subject to the presence of developed countries, such as the U.S., Canada, etc. Furthermore, the presence of latest healthcare facilities and favorable reimbursement policies are also projected to support the development of the cochlear implants market in the region in the forecast timeframe.

    *Request a Discount On This Report: *https://www.zionmarketresearch.com/requestdiscount/cochlear-implants-market

    Asia Pacific is expected to be the third largest and fastest growing regions in the forecast timeframe, owing to the increased prevalence of hearing defects, increase in the number of neonates born with hearing defects, and the presence of developing economies, such as India, China, etc. Furthermore, growing healthcare facilities and an increase in the per capita income with increased product awareness among people are the major factors expected to promote the growth of the cochlear implants market in the forecast timeframe.

    Latin American and the Middle Eastern and African markets are expected to grow moderately in the forecast timeframe, owing to the lack of hygienic practices and an increased prevalence of ear infections coupled with favorable government initiatives for raising product awareness and improvements made related to healthcare facilities are expected to promote the growth of the cochlear implants market in this region.

    Browse the full *"Cochlear Implants Market by Type (Unilateral and Binaural) by Application (Children and Adult): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017 – 2024"* report at https://www.zionmarketresearch.com/report/cochlear-implants-market

    Some major players of the cochlear implant market include cochlear Ltd., MED-EL, Advanced Bionics AG (Sonova), William Demant Holding A/S, and Nurotron Biotechnology Co. Ltd., among others.

    *Inquire more about this report before purchase @ *https://www.zionmarketresearch.com/inquiry/cochlear-implants-market

    *This report segments the global cochlear implants market as follows:*

    *Global Cochlear Implants Market: Type Segment Analysis*

    · Unilateral
    · Binaural

    *Global Cochlear Implants Market: Application Segment Analysis*

    · Adult
    · Children

    *Global Cochlear Implants Market: Regional Segment Analysis*

    · North America

    · The U.S.

    · Europe

    · UK
    · France
    · Germany

    · Asia Pacific

    · China
    · Japan
    · India

    · Latin America

    · Brazil

    · The Middle East and Africa

    *Related Reports:*

    · *Hearing Aids Market: *https://www.zionmarketresearch.com/report/hearing-aids-market
    · *Sleep Apnea Devices Market:* https://www.zionmarketresearch.com/report/sleep-apnea-devices-market
    · *Artificial Tendons and Ligaments Market: *https://www.zionmarketresearch.com/report/artificial-tendons-and-ligaments-market
    · *Heart Pump Device Market:* https://www.zionmarketresearch.com/report/heart-pump-device-market
    · *Medical Carts Market:* https://www.zionmarketresearch.com/report/medical-carts-market                       

    *About Us:*

    Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

    *Follow Us LinkedIn: *https://www.linkedin.com/company/zion-market-research
    *Follow Us Twitter: *https://twitter.com/zion_research

    *Blog:* http://www.intenseresearch.com | http://www.mrsresearchgroup.com | http://www.marketresearchtrade.com | https://qyresearchgroup.com | http://marketnreports.com | https://zmrnewsjournal.us | http://www.e-marketresearch.com

    *Contact Us:*

    Joel John
    244 Fifth Avenue, Suite N202
    New York, 10001, United States
    Tel: +49-322 210 92714
    USA/Canada Toll-Free No.1-855-465-4651
    *Email:* sales@zionmarketresearch.com

    *Website:* https://www.zionmarketresearch.com

    * Blog:* http://zmrblog.com Reported by GlobeNewswire 1 hour ago.

    0 0

    Visit stand 30 at the 5th Digital Pathology and AI Congress, London to learn how Inspirata is igniting digital pathology with new software features and functions in release v2.0.8.

    London, United Kingdom, Dec. 05, 2018 (GLOBE NEWSWIRE) -- London, United Kingdom, December 5, 2018/Globe Newswire – Cancer informatics and digital pathology workflow solution provider Inspirata® Europe, Ltd. today revealed it has entered into a partnership agreement with Hamamatsu Photonics affording shared customers with the ability to view native Hamamatsu .ndpi images within Inspirata’s Dynamyx™ digital pathology software.  Inspirata and Hamamatsu will also be showcasing the many benefits this technical partnership will bring to clinical laboratories as part of both providers’ scheduled participation in Digital Pathology & AI Congress, London.

    “By bringing on new leading scanner partners and enhancing the viewer capabilities, Dynamyx™ is positioning itself as the nucleus of a digital pathology ecosystem,” says Inspirata Founder Dr. Mark Lloyd.  “We are thrilled to be seamlessly integrated with the high quality Whole Slide Images produced by the diverse line of Hamamatsu scanners, as it gives our joint clients an exemplary user experience while protecting any previous investment in scanners and allowing for the growth of new instruments.”

    The Hamamatsu integration is included as part of release v2.0.8, comes just three months after Inspirata’s last major update and further exemplifies the partnership philosophy which underpins their mission and vision.  “We are bringing scanners, image analysis algorithms and AP-LIS/ LIMS vendors together to create a comprehensive digital workflow which empowers pathologists to work more efficiently and effectively,” says General Manager of Inspirata Europe, Ltd. Tim Wing. “With the Royal College of Pathologists’ 2018 Histopathology Workforce Survey^i surfacing just three percent of histopathology departments in the UK possess sufficient staff to meet demand, equipping those covering the shortfall to work smarter is imperative.  The pathology and laboratory community are desperately appealing for providers to work closer together for the betterment of patients and this partnership speaks to what can be achieved when they do.”

    “Hamamatsu Photonics is delighted to collaborate with Inspirata and is excited that our renowned range of WSI scanners will form a key part of such an integrated digital pathology workflow solution,” explains Hamamatsu Photonics Europe Nanozoomer Product Manager Emmanuel Pirson.  “We expect this partnership to contribute to an accelerated uptake of integrated digital pathology solutions within the European clinical market. Likewise, this collaboration represents just one of a number of steps our Company is taking to increase awareness and acceptance of digital pathology.”

    With orders placed for a single Nanozoomer S60 and two Nanozoomer S360, one of the early beneficiaries of the Inspirata and Hamamatsu partnership will be Path Links in Lincoln.  Representing one of the largest clinical pathology networks in the UK, Path Links serves a population of approximately one million and processes four and a half million specimens each year.  “When undertaking a transformation as significant as migrating from analogue to digital pathology, it is essential to have the freedom as an institution to select the blend of providers which most appropriately match your requirements,” says Mick Chomyn, Path Links General Manager.  “Having spent the last few months really putting them through their paces, we are confident that the Hamamatsu scanners represent an excellent fit and will serve to complement our existing scanner investments.”

    Located at stand 30 at Digital Pathology & AI Congress, event attendees will be able to participate in interactive demonstrations of the Dynamyx digital pathology workflow software and explore for themselves how real-time collaboration, case-sharing, workflow algorithms and AI-based image analysis APIs functionality could be utilized to assist their laboratory reduce turnaround times.  In addition, Inspirata and Hamamatsu will be participating in a joint Congress workshop in which they will spotlight their new integration on December 7^th 1.45-2.30.  Registration for this workshop^ii is now open and can be accessed via the link here.

    The pressures on pathology departments are increasing.  Inspirata’s advanced workflow-centric tools and ‘open’ architecture are critical enablers of digital adoption as a way to alleviate these challenges.

    *About Hamamatsu Photonics *

    Hamamatsu has a decade of real world experience in delivering sophisticated whole slide imaging (WSI) solutions across the globe. Hamamatsu’s NanoZoomer whole slide scanner series quickly transform entire histology and cytology glass slides into diagnostic-quality digital images for duplication, annotation, storage, retrieval, and image sharing. Our intuitive viewer software and patented navigation map technique enable users to scan slides in a variety of modes and share images across networks. Applications include routine and computer-aided diagnosis in laboratories, research, education, and telepathology.

    *About Inspirata Europe Ltd.*

    Inspirata^® Europe Ltd. provides oncology diagnostics workflow solutions that span digital pathology; diagnostic and predictive assays; and precision medicine. It also offers cancer informatics workflows that, in combination with its Natural Language Processing (NLP) and Artificial Intelligence (AI) algorithms structures unstructured case files and clinician notes to provide key insights for oncology-specific clinical and operational activities as well as cancer reporting. Inspirata’s flagship solution is its Cancer Information Data Trust (CIDT) that generates a longitudinal view of oncology patients—from diagnosis, through treatments and therapies, to outcomes. The CIDT has extensive applications in clinical decision support, research, education, drug discovery and clinical trials enrollment. Its use will extend to physicians, patients, researchers, pharma and others. For more information, please visit www.inspirata.com or contact info@inspirata.com.

    --------------------

    ^i Royal College of Pathologists Histopathology Workforce Survey – link here

    ^ii The workshop is only open to those registered to attend Digital Pathology & AI Congress.

    *Attachments*

    · Hamamatsu Images in Dynamyx Slide Tray
    · Hamamatsu Images in Dynamyx Image Viewer

    CONTACT: Graeme Collins
    Inspirata Europe Ltd
    +44 (0) 7854 664168
    gcollins@inspirata.com Reported by GlobeNewswire 39 minutes ago.

    0 0

    Enhanced prevention measures, especially against tobacco and electronic cigarettes, combined with access to innovative treatments can help tackle rising lung cancer cases in Europe, a new study funded by the industry has found. Reported by EurActiv 37 minutes ago.

    0 0

    EQS-News / 05/12/2018 / 14:36 UTC+8*Vixtel Technologies Holdings Limited
    (Stock Code: 1782.HK)*

    *Entering Into Strategic Cooperation with NetScout,
    the Largest Global Network Performance Management Giant,
    Vixtel Technologies Makes Efforts in the 5G Network Performance Monitoring Market to Seize Huge Opportunities in China's Telecom Industry*

    *Vixtel Technologies Holdings Limited* (the "Company" or "Vixtel Technologies", together with its subsidiaries, the "Group", stock code: 1782.HK) is pleased to announce on 4^th December 2018 that the Company has signed a cooperation agreement with the world's largest network performance monitoring and diagnostics company (NPMD) - NetScout Systems Inc. ("NetScout", NASDAQ stock code: NTCT) to become NetScout's "Telecom Operator Market Strategic Partner" in China at the highest Platinum Partner level. The Company will focus on the 5G network virtualization monitoring market to provide a full range of Software Defined Network (SDN) and Network Function Virtualization (NFV) performance management services, so as to gain more orders from China's telecom operators.

    In this agreement, Vixtel Technologies will obtain the distribution right of NetScout products until terminated with mutual consent of the two parties. NetScout is the world's largest NPMD company with a state-of-the-art analytical tool system. Especially in the fields of NFV and virtualization performance management, NetScout is one of the few enterprises that has established a formal partnership with VMWARE, a US software company which provides cloud computing and hardware virtualization, and Openstack, the cloud computing software in which NASA has conducted research and development. Hence NetScout fully masters the technology to monitor the performance of 5G network virtualization. The strategic cooperation with NetScout will help Vixtel Technologies to enrich its product lines and service scopes, to provide a comprehensive and sophisticated application performance management solutions in 5G network virtualization for China's telecom customers, thereby enhancing the competitiveness of Vixtel Technologies.

    *Mr. Sie Tak Kwan*, the *CEO of Vixtel Technologies*, is excited about the cooperation, 'The cooperation is an important step in the Company's development strategy. At present, China Mobile is our main telecom operator customer. With the increasing popularity of digital homes in China and the gradual adoption of 5G networks, Vixtel Technologies has put forward the strategic goal of Focus On 5G. In addition to increasing R&D investment and continuing to strengthen the Company's performance management solutions for the digital homes, the Company is also enhancing its technical solutions in 5G networks by forming the strategic partnership with NetScout. The 5G network is a virtualized network, while NetScout has been the leading enterprise providing virtualized network performance management in the United States and Europe. This time, Vixtel Technolgies's cooperation with NetScout in the telecom field does not only embody our technologies and marketing capabilities, but also reflects NetScout's confidence in China's telecom market."

    He continued, "Since the initial completion of 4G construction, China operators have not made large-scale investments in mobile networks for many years. I believe that under this wave of 5G construction, the demand of operators for network performance management will increase substantially, which will bring a large number of orders to the industry. We are confident to benefit from the 5G boom through the formation of a comprehensive leading performance management solution covering the users and the core network. According to the forecast of Frost & Sullivan, a famous international consulting company, the total value of the Chinese application performance market is expected to exceed RMB5 billion by 2020. Telecom service providers are an important sector, providing the enterprises with a rare golden development opportunity. Accelerated deployment of the state-led 5G network, coupled with deep penetration of the Internet of Things and smart homes, we will increase investment in research and development to meet the needs of our customers and seek sustainable growth for the Company."

    *Mr. Michael Chang, NetScout's Sales Director in Greater China* said: 'We are confident about this strategic co-operation. On one hand, NetScout could leverage on Vixtel Technologies' extensive network in China's telecom market to rapidly promote our international leading network performance management system. On the other hand, this is a mutually beneficial agreement in which Vixtel Technologies could enhance its product portfolio, demonstrate its core market value and expand its market shares."

    - END -

     

    *About NetScout*
    Established in 1984, NetScout has its headquarter in Massachusetts, USA. Same as Vixtel Technologies, NetScout provides tailor-made on-premises Application Performance Management services for its customer. It is the largest network performance monitoring and diagnostics company in the world. Leverage on its strong integration capability and product performance, its client ranged from medium to large scale enterprises, government agencies as well as telecom service providers. It is listed on NASDAQ, with a market value of approximately USD$2 billion and a P/E ratio of approximately 58 times.*About Vixtel Technologies Holdings Limited *
    Vixtel Technologies Holdings Limited (Stock code: 1782) is a market leader in China's application performance management ("APM") industry. It mainly provides APM products and service solutions to telecom operators, cable television suppliers, power companies and large scale enterprises. Its main business includes overall APM system solutions, software development services, technical services and sales of standard hardware and software. Products of the company include NetVista platform, Trade QoS system and software-as-a-service (SaaS) platform etc.

    This press release is made by DLK Advisory Limited on behalf of *Vixtel Technologies Holdings Limited*.

    *DLK Advisory 金通策略*
    Tel: +852 2857 7101
    Fax: +852 2857 7103
    Document: http://n.eqs.com/c/fncls.ssp?u=PQLYNGEANT
    Document title: [1782.HK Vixtel Technologies]Entering Into Strategic Cooperation with NetScout, the Largest Global Network Performance Management Giant, Vixtel Technologies Makes Efforts in the 5G Network Performance Monitoring Market to Seize Huge Opportunities in Chin
    05/12/2018 Dissemination of a Financial Press Release, transmitted by EQS Group.
    The issuer is solely responsible for the content of this announcement.

    Media archive at www.todayir.com Reported by EQS Group 42 minutes ago.

    0 0

    According to the report, the global gluten-free product market was valued at around USD 4.72 Billion in 2017 and is expected to reach approximately USD 7.60 billion by 2024, growing at a CAGR of around 7.12% between 2018 and 2024.

    New York, NY, Dec. 05, 2018 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled *“Gluten Free Product Market By Product (Bakery Products, Pasta & Pizza, Snacks & RTE Meals, Baby Food, Condiments & Dressings, and Other) and By Distribution Channel (Business To Business [Hospitality Services, Hotels & Restaurants, and Online Channel] and Business To Consumer [Supermarket/Hypermarket, Conventional Stores, Specialty Services, and Online Channel]): Global Industry Perspective, Comprehensive Analysis, And Forecast, 2017–2024”*. According to the report, the global gluten-free product market was valued at around USD 4.72 Billion in 2017 and is expected to reach approximately USD 7.60 billion by 2024, growing at a CAGR of around 7.12% between 2018 and 2024.

    Gluten is the protein found in various grains, such as rye, wheat, barley etc.  According to an independent survey, around 20% of consumers globally avoid certain foods due to allergies or intolerances. This provides an opportunity for many manufacturers to launch allergen-free products. Gluten intolerant population might suffer from autoimmune diseases, such as celiac. Increasing occurrences of celiac patients globally and growing awareness among the consumers regarding healthy diet and its importance is anticipated to fuel the gluten-free product market. Moreover, celiac is a genetic disorder and can be transferred from parents to their kids, which leads to the demand for gluten-free product for babies market.

    *Browse through 37 Tables & 18 Figures spread over 110 Pages and in-depth TOC on “Global Gluten-Free Product Market: By Product Type, Size, Share, Industry Segments, Demand, Analysis and Forecast, 2017–2024”.*

    *Request Free Sample Report of Global Gluten-Free Product Market Report @ *https://www.zionmarketresearch.com/sample/gluten-free-product-market

    A growing number of gluten-intolerant working people globally is anticipated to spurt the gluten-free product market growth in the near future. This, in turn, is likely to generate a significant demand for gluten-free snacks and RTE products. This is encouraging the major market players to invest in gluten-free products. In addition, various local brands have started manufacturing gluten-free products, such as bread, pizzas, pasta etc. Moreover, the growing millennial population and rising standards of living are anticipated to boost the gluten-free product market growth. 

    By product, the global gluten-free product market is classified into bakery products, pasta and pizza, snacks and RTE meals, baby food, condiments and dressings, and others. The bakery products segment accounted for a substantial revenue share of the market in 2017. By distribution channel, the global gluten-free product market is segmented into business to business and business to consumer. The business to consumer distribution channel is anticipated to show a significant escalation in the near future in terms of revenue, owing to the growing popularity of convenience stores and supermarkets/hypermarkets and thriving e-commerce sector. 

    *Download Free Report PDF Brochure: *https://www.zionmarketresearch.com/requestbrochure/gluten-free-product-market

    North America is projected to show considerable growth in the gluten-free product market, owing to the increasing demand for gluten-free products. The demand for gluten-free products in this region is driven by an increasing preference for ancient grains, such as sorghum. Growing health awareness and benefits associated with gluten-free products is anticipated to boost the gluten-free product market in North America in the forecast timeframe. There has been increasing use of gluten-free products, owing to increasing occurrences of celiac disease. Intolerance to gluten and growing awareness regarding problems associated with gluten are anticipated to boost the gluten-free product market. In addition, the high demand for gluten-free products from the millennial population is anticipated to boost the gluten-free product market across the region in the near future. The increasing use of healthy alternatives, such as sweet sorghum, is used to produce gluten-free syrup and used as a natural sweetener for whiskey, rum etc. is anticipated to boost the gluten-free product market in North America in the near future. Moreover, busy/hectic lifestyle, changing food habits, and growing preference for healthy food products are anticipated to boost the gluten-free product market.

    Majority of the European population is focusing on gluten-free products, owing to rising cases of celiac disease. In addition, there is a significantly high demand for gluten-free bakery products, such as, cookies, bread, and snacks, which are anticipated to boost the gluten-free product market. The UK is the major marketplace with growing demand for gluten-free products. This, in turn, is anticipated to boost the gluten-free product market in this region.

    *Request For The Discount: *https://www.zionmarketresearch.com/requestdiscount/gluten-free-product-market

    The Asia Pacific gluten-free product market is anticipated to show a significant growth in the near future. The increasing consumer preference for healthy and high-quality food products is anticipated to drive the gluten-free product market. In addition, increasing disposable income and willingness to pay more for healthier food products are projected to increase the gluten-free product market demand in this region. China is anticipated to witness good growth in the gluten-free product market during the forecast timeframe, owing to the rising per capita income along with increasing population.

    The Latin American gluten-free market is expected to demonstrate moderate growth in the forecast timeframe. This is mainly due to the growing application of gluten-free grains in food and beverages industry. Gluten-free grains are used increasingly as natural sweeteners in various beverages, such as whiskey, rum, etc. Growing tourism industry in this region is anticipated to trigger the food and beverages industry, which in turn, is expected to positively influence the gluten-free product market growth.

    Browse the full *"Gluten-Free Product Market By Product (Bakery Products, Pasta & Pizza, Snacks & RTE Meals, Baby Food, Condiments & Dressings, and Other) and By Distribution Channel (Business To Business [Hospitality Services, Hotels & Restaurants, and Online Channel] and Business To Consumer [Supermarket/Hypermarket, Conventional Stores, Specialty Services, and Online Channel]): Global Industry Perspective, Comprehensive Analysis, And Forecast, 2017–2024" *report at https://www.zionmarketresearch.com/report/gluten-free-product-market

    The Middle Eastern and African gluten-free product market is anticipated to show slow growth in the forecast span, owing to low awareness regarding gluten along with the complications associated with it.

    Some of the key players of the gluten-free product market are Alara Wholefoods Ltd., Sanitarium Health & Wellbeing Company, Amy’s Kitchen, Bagrrys India Ltd., Country Choice, General Mills, Kellogg’s, Nestle, Nature’s Path, Raisio, Uncle Tobys, Weetabix, MOMA, and Quaker Oats Company, among others.

    *Inquire more about this report before purchase @ *https://www.zionmarketresearch.com/inquiry/gluten-free-product-market

    *This report segments the global gluten-free product market as follows:*

    *Global Gluten-Free Product Market: Product Category Segment Analysis*

    · Bakery Products
    · Pasta & Pizza
    · Snacks & RTE Meals
    · Baby Food
    · Condiments & Dressings
    · Others

    *Global Gluten-Free Product Market: Distribution Channel Segment Analysis*

    · Business To Business 

    · Hospitality Services
    · Hotels & Restaurants
    · Online Channel

    · Business To Consumer

    · Supermarket/Hypermarket
    · Conventional Stores
    · Specialty Services
    · Online Channel

    *Global Gluten-Free Product Market: Regional Segment Analysis*

    · North America

    · The U.S.

    · Europe

    · UK
    · France
    · Germany

    · Asia Pacific

    · China
    · Japan
    · India

    · Latin America

    · Brazil

    · The Middle East and Africa

    *Browse More Related Reports:*

    · *Garlic Extract Market:* https://www.zionmarketresearch.com/report/garlic-extract-market
    · *Kefir Market:* https://www.zionmarketresearch.com/report/kefir-market
    · *Seasonings and Spices Market: *https://www.zionmarketresearch.com/report/seasonings-and-spices-market
    · *Food Enzymes Market:* https://www.zionmarketresearch.com/report/food-enzymes-market
    · *Functional Flour Market:* https://www.zionmarketresearch.com/report/functional-flour-market                           

    *About Us:*

    Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

    *Follow Us LinkedIn: *https://www.linkedin.com/company/zion-market-research
    *Follow Us Twitter: *https://twitter.com/zion_research

    *Blog:* http://www.intenseresearch.com | http://www.mrsresearchgroup.com | http://www.marketresearchtrade.com | https://qyresearchgroup.com | http://marketnreports.com | https://zmrnewsjournal.us | http://www.e-marketresearch.com

    *Contact Us:*

    Joel John
    244 Fifth Avenue, Suite N202
    New York, 10001, United States
    Tel: +49-322 210 92714
    USA/Canada Toll-Free No.1-855-465-4651
    *Email:* sales@zionmarketresearch.com

    *Website:* https://www.zionmarketresearch.com

    * Blog:* http://zmrblog.com Reported by GlobeNewswire 31 minutes ago.

    0 0

    TUV Rheinland: a critical step forward for MicroP medical certifications for dental handpiece TAIPEI, Dec. 5, 2018 /PRNewswire/ -- The continued growth of the global medical device industry means requisite safety testing and certification for medical devices that can be quite challenging before they are released to market. On November 30, MicroP, a dental handpiece maker in Taiwan, announced that it has successfully obtained ISO 13485:2016 certification, as well as CE Marking and FDA 510(k) approvals. In addition to announcing that it had obtained all three certifications, it also announced that AG Neovo Dental, a well-known American dental equipment brand, had also placed orders with the company.  As a partner of the NARLabs Medical Device Alliance, TUV Rheinland was pleased to witness MicroP, a young start-up, finish the complete preparation and certification process, together with the National Applied Research Laboratories cooperations.  Max Lyou, Managing Director of TUV Rheinland Taiwan, was on hand to witness the contract-signing ceremony and express his felicitations.MicroP obtained certifications from TUV Rheinland

    MicroP, a young start up, began developing dental handpieces in 2013.  All R&D is conducted in-house, and 95% of all parts are produced internally as well. The newly certified dental handpiece product is a basic medical device used in all dental clinics, which makes use of high-precision mechanical machining technology. The technical threshold is very high due to its stringent safety and quality requirements, such as high rotation speed, dynamic balance, and low noise. Only four Taiwanese dental instrument makers have successfully obtained FDA approvals for this product over the last decade.  MicroP is now one of the few to have obtained CE Marking, quality management systems certification, and FDA approval all at once, in under two years. 

    New start-ups for medical devices have limited resources. Finding the right medical device certification body can be critical to successful certification. Some vendors go through the application process only to discover that their certification body has not been accredited by the International Accreditation Forum (IAF). Not being able to use their hard-won certification means time and money wasted. The conformity requirements for medical devices are particularly strict and rigorous. Finding a certification body with proper international accreditation as well as a complete testing and auditing team is the only way to steer a clear path through the complex review process.

    TUV Rheinland headquarters is a notified body authorized by the Central Authority of the Länder for Health Protection (ZLG), the German equivalent of Taiwan's Ministry of Health and Welfare. Mutual recognition for ZLG in all EU member states, and its leadership position, means greater acceptance in the European market. MicroP's medical device CE Marking was approved by TUV Rheinland headquarters in Germany, and thus is trusted by European medical device customers. In addition to dental handpieces, applications for the CE Marking under the EU MDR directive can also be made for non-intrusive medical devices such as blood oxygen monitors, blood pressure monitors, ear thermometers, X-ray machines, and nebulizers (for asthma) intended for sale in Europe.

    At the same time, the emphasis in ISO 13485 quality management system certification is on risk management. It is essential to ensure that products can satisfy the requirements set by the local authorities, no matter which market they are destined for. With an application for ISO 13485 certification with TUV Rheinland, applications for EU MDR, IVDR, and MSDAP certification can also be made at the same time, proving that the medical device's production process complies with international medical device quality management standards and expanding the channels for market access.

    MicroP's development of a low-noise, high-speed dental handpiece that has gained ISO 13485:2016 certification for medical devices, CE Marking, and FDA 510k clearance all at the same time is proof that young start-ups can shorten their learning curve and quickly reach their target goals if they choose the right value partner. 

    Photo - https://photos.prnasia.com/prnh/20181205/2318056-1 Reported by PR Newswire Asia 15 minutes ago.

    0 0

    SINGAPORE and HONG KONG, Dec. 5, 2018 /PRNewswire/ -- Klook, a world leading travel activities and services booking platform, and Shangri-La Hotels and Resorts, Asia Pacific's leading luxury hotel group, today announced a global strategic partnership that will enable hotel guests to directly access the world's best activities to enhance their hotel and destination experience. With this partnership, Shangri-La can provide more differentiated experiences and benefits important to guests and Golden Circle members, including earning and redeeming Golden Circle Award Points from local experiences and at over 500 restaurants and CHI, The Spa within Shangri-La. Klook's expertise in meeting the needs of the "on-the-go", tech-savvy, millennial traveller will complement Shangri-La's offerings and help define a new model of creating one's own journey.

    "By delivering additional hotel and in-destination features, we are strengthening the value proposition for guests in line with their widening needs and giving them more inspiring choices during their travels," said Irene Lin, Shangri-La Executive Vice President -- Marketing. "Collaborating with Klook will allow us to offer guests a deeper discovery of local experiences and we're excited the partnership will open up many more memorable moments to guests in and beyond Shangri-La hotels worldwide."   

    Anita Ngai, Chief Revenue Officer at Klook, said, "The luxury traveller is more tech-savvy than ever as they are seeking smart, convenient, and cash-free solutions, and we're continually enriching Klook's services to make the platform suitable and engaging for all types of travellers. We're excited to be innovating on a series of initiatives with Shangri-La - Klook Concierge and Golden Circle redemption programme are just the start of an exciting partnership ahead."

    Klook and Shangri-La will initially collaborate on the following:

    *Klook Concierge:* In December 2018, Shangri-La Hotel, Bangkok; Shangri-La Hotel, Singapore and Kowloon Shangri-La, Hong Kong will be the inaugural hotels to debut the Klook Concierge service.

    Guests can discover and book Klook experiences throughout their stay via a tablet at the hotel concierge, even at the last minute, and redeem via a QR code or e-voucher. In addition, Shangri-La's Golden Circle members can earn Golden Circle Award Points for each experience booked through the Klook Concierge.

    To mark the partnership launch, Shangri-La will offer Golden Circle members 100 Golden Circle Award Points on every booking on the Klook Concierge, while Klook will offer a platform-wide discount of 5% on its experiences until 28 February 2019.

    *Golden Circle Award Point Redemption*: All Shangri-La's Golden Circle members have the option to redeem their points for selected Klook experiences in Singapore, Bangkok, Beijing and Shanghai in December 2018. This will expand to over 60,000 Klook experiences in quarter three 2019, from must-eats and unique tours to local transport and popular attractions. The Klook activity redemption initiative with Golden Circle members is set to be the first of its kind for a luxury hotel group.

    *Marketing Collaborations*: In 2019, Klook and Shangri-La will jointly launch various marketing initiatives, as well as make unique Shangri-La experiences available on the Klook platform. More information will be announced at the time of launch.

    *About Klook*

    Founded in 2014, Klook is one of the world's leading travel activities and services booking platforms. Klook gives travellers a seamless way to discover and book popular attractions, tours, local transportation, best foods and must-eats, and unique experiences around the world on its website and award-winning app ('Best of 2015' & 'Best of 2017' by Google Play and Apple App Store). With Klook's innovative technologies, travellers can book on-the-go and redeem the services by using QR codes or e-vouchers. Each day, Klook empowers countless travelers to indulge in their wanderlust and spontaneity through over 60,000 offerings in more than 250 destinations.

    With a team of over 800 across 16 offices worldwide, Klook's services are available in eight languages, supporting 36 currencies. It has raised a total of US$300 million investment from world-renowned investors including Sequoia China, TCV, Matrix Partners, and Goldman Sachs. Get inspired by Klook at www.klook.com, the company blog or @Klook.

    *About Shangri-La Hotels and Resorts*

    Hong Kong-based Shangri-La Hotels and Resorts, one of the world's premier hotel owners and operators, currently manages over 100 hotels globally in 76 destinations under the Shangri-La, Kerry, Hotel Jen and Traders brands. Prominently positioned in Asia, the group has established its hallmark of "hospitality from the heart" over four decades in Asia Pacific, the Middle East, Europe, North America and the Indian Ocean. The group has a substantial development pipeline with upcoming projects in Australia, Bahrain, mainland China, Cambodia, Indonesia, Malaysia and Saudi Arabia. For more information, visit www.shangri-la.com.

    Related Links :

    http://www.klook.com Reported by PR Newswire Asia 15 minutes ago.

    0 0

    *KONE Corporation, press release, December 5, 2018*

    KONE Corporation, a global leader in the elevator and escalator industry, has been selected to equip the World Expo taking place in Dubai in the United Arab Emirates (UAE) in 2020-2021 with its safe and energy-efficient people flow solutions. Expo 2020 Dubai is scheduled to run between October 20, 2020 and April 10, 2021 and anticipated to attract some 25 million unique visitors under the main theme of "Connecting Minds, Creating the Future." 

    The Expo 2020 Dubai grounds are designed in the shape of a flower, with Al Wasl Plaza the main square and central visitor hub that connects three, petal-shaped Thematic Districts, each dedicated to one of the Expo's sub themes: mobility, sustainability and opportunity. KONE will equip the Thematic Districts and Al Wasl Plaza with a total of 151 KONE MonoSpace® elevators, 6 dumbwaiters, 6 platform elevators, one elevator for people with limited mobility, and 16 KONE TravelMaster(TM) 110 escalators. The KONE E-Link(TM) facility management tool will enable the performance of all the equipment to be monitored from a single location. 

    "We are delighted to contribute to smooth people flow at Expo 2020 Dubai, which promises to be a stimulating showcase of the latest technologies and innovations from around the globe. I am particularly excited that this will be the first World Expo hosted in the Middle East," said Pierre Liautaud, KONE executive vice president for South Europe, Middle East and Africa. 

    Expo 2020 Dubai has set the target of achieving the LEED Gold certification for its permanent structures, which will continue to be utilized after the close of the exhibition. The 4.38 square kilometer Expo 2020 Dubai site will live on as a new smart city area to be called District 2020. Plans for the Thematic districts include 6 pavilion buildings designed for commercial, residential and retail use.

    Bureau Expo Dubai 2020 is the developer of the project, and the main contractor for the Thematic Districts is Al Futtaim Carillion. Contractors for the buildings in Al Wasl Plaza are Al Futtaim Carillion and Laing O'Rourke Middle East.  

    The architects for the Thematic Districts and Al Wasl Plaza are Hopkins Architects Dubai, and Adrian Smith + Gordon Gill Architecture, respectively.

    KONE booked the order in the first quarter of 2018. 

    *Note to editors*:
    KONE is one of Finland's National Partners for Expo 2020 Dubai. Link to press release on Business Finland's website.

    *For further information, please contact*: 
    Hanna Rutanen, Director, External Communications, KONE Corporation, tel. +358 41 5071361, media@kone.com

    *Read more *
    Official website of Expo 2020 Dubai: www.expo2020dubai.com

    Previous press releases are available at http://www.kone.com/en/news-and-insights/releases/ including: 
    October 12, 2018: Forbes recognizes KONE as one of the best employers in the world
    June 1, 2018: KONE listed as one of the world's most innovative companies by Forbes
    May 7, 2018: KONE to equip Dubai Hills Mall in the United Arab Emirates 
    January 10, 2018: KONE wins order for WOW hotel apartments tower in Dubai

    More information on KONE Middle East available at https://www.kone.ae including the following press release: 
    June 26, 2018: A market first: KONE introduces ground-breaking maintenance services to the UAE

    *About KONE* 
    At KONE, our mission is to improve the flow of urban life. As a global leader in the elevator and escalator industry, KONE provides elevators, escalators and automatic building doors, as well as solutions for maintenance and modernization to add value to buildings throughout their life cycle. Through more effective People Flow®, we make people's journeys safe, convenient and reliable, in taller, smarter buildings. In 2017, KONE had annual net sales of EUR 8.9 billion, and at the end of the year over 55,000 employees. KONE class B shares are listed on the Nasdaq Helsinki Ltd. in Finland.
    www.kone.com Reported by GlobeNewswire 9 minutes ago.

    0 0

    *Press release*
    Stockholm 5  December 2018

    *Sweden's CFOs remain optimistic about the future, although the upward trend is waning in strength. The expansive agenda is continuing, and the willingness to invest and hire among Swedish companies is still at the top compared with other EU countries. The greatest risk is the continued shortage of qualified talent, both for Swedish companies and in Europe in general. A majority of Sweden's CFOs believe that the trade war will escalate and lead to higher costs, at the same time that the level of external uncertainty is considered to be normal or even slightly lower.*

    The Deloitte/SEB CFO Survey is conducted twice a year and aims to illuminate changes in sentiment among Sweden's CFOs. This past autumn's report shows that optimism about future business opportunities ahead of the coming year has grown for the fifth survey in a row, but that the pace of growth once again slowed. The growing optimism among Sweden's CFOs stands in contrast to the trend in the rest of Europe, where it declined slightly in the autumn survey.

    "The growth in optimism has even been longer in duration than during the recovery following the financial crisis. This, combined with a slowing pace of growth, suggests some concerns that we are nearing an economic top," says *Karl Steiner*, economist at SEB.

    *Expansive agenda intact*

    As in the spring, organic growth is a top priority for companies. A slightly lower willingness to use surplus liquidity for investments points cautiously in a defensive direction, however, a continued strong belief in an increase in hiring and higher capital outlays points rather to an intact investment agenda. Moreover, Sweden's CFOs - along with their Norwegian counterparts - are the only in Europe who rank the external uncertainty as normal or even slightly lower than usual.

    "The survey also shows that despite the decreasing pace of growth in optimism, Swedish companies are continuing along the expansive agenda that they adopted last autumn," says *Henrik Nilsson*, partner at Deloitte.

    *Competence shortage still the greatest risk*

    As in the past spring, the biggest risk is the shortage of competence - this has been expressed by CFOs both in Sweden and in Europe in general. Above all it is specific technical competence and the right work life experience that are hard to match. The solutions that have mainly been recommended include retraining existing personnel and using temporary resources. However, in sharp contrast to many other countries in Europe, interest in greater automation as a solution for the shortage of competence is tepid among Sweden's CFOs.

    "Ninety per cent responded that their company to some extent has a hard time finding the right competences, which clearly shows that this is a growing problem," says Henrik Nilsson*, *adding: "The low interest in automation is a bit surprising, but the specific technical competence that is in demand seems to lend itself less well for automation, while Swedish companies have likely already come comparatively far with respect to automation."

    *Escalating trade war making it harder for companies*

    For the second survey in a row, slowing growth is ranked as the second largest risk. This is closely interwoven with the international trade war, which a majority of Sweden's CFOs believe will escalate, at the same time that there are few who expect it to de-escalate. The biggest effects of a trade war are believed to be higher costs for companies and that it will be harder to make investment decisions.

    "The belief in an escalation of the trade war is strongest among internationally dependent sectors, such as the engineering industry," says Karl Steiner. For them, it is mainly higher raw material costs that are the main area of concern, while import-dependent sectors are worried that negative currency effects will lead to higher purchasing prices."*About the Deloitte/SEB CFO Survey*

    The Deloitte/SEB Survey aims to highlight changes in sentiment among Swedish CFOs, various sectors, and compared with the general sentiment in the rest of Europe, and thereby convey an understanding of economic and financial trends. It is published twice yearly and is conducted in Sweden and in 19 other European countries. Read the complete report, www.cfosurvey.se

    *For further information, please contact*
    Karl Steiner, Economist SEB Research
    070-332 3104, karl.steiner@seb.se
     
    Henrik Nilsson, partner, Deloitte
    073-397 1102, henrik.nilsson@deloitte.se *Press Contact*
    Frank Hojem, Group Press Officer SEB
    070-763 9947, frank.hojem@seb.se
     
    Christer Ahlgren, press contact, Clients &Industries, Deloitte
    0708-14 23 20, christer.ahlgren@deloitte.se
     
    SEB is a leading Nordic financial services group with a strong belief that entrepreneurial minds and innovative companies are key in creating a better world. SEB takes a long-term perspective and supports its customers in good times and bad. In Sweden and the Baltic countries, SEB offers financial advice and a wide range of financial services. In Denmark, Finland, Norway, Germany and UK the bank's operations have a strong focus on corporate and investment banking based on a full-service offering to corporate and institutional clients. The international nature of SEB's business is reflected in its presence in some 20 countries worldwide. On September 30, 2018, the Group's total assets amounted to SEK 2,777 billion while its assets under management totalled SEK 1,871 billion. The Group has around 15,000 employees. Read more about SEB at http://www.sebgroup.com.

     

    *Attachments*

    · CFO Survey Fall 2018 Final.pdf
    · Press Release (PDF).pdf Reported by GlobeNewswire 9 minutes ago.

    0 0

    Press Release, December 5, 2018

    *Second quarter, August - October 2018*

    · Net sales increased by 15.4 percent to SEK 2,151 million (1,864).
    · Organic growth was 9.1 percent (4.2).
    · Operating profit (EBIT) totalled SEK 189 million (144).
    · The operating margin was 8.8 percent (7.7).
    · Profit after tax amounted to SEK 126 million (101).
    · Earnings per share totalled SEK 2.43 (1.95).
    · Cash flow from operating activities amounted to SEK 87 million (100).

    *Roland Kasper, President and CEO, comments:*
    "During the second quarter, growth was recorded at 15.4 percent, of which 9.1 percent was organic. All regions reported good growth, especially North America and Asia. Our gross margin showed a degree of improvement through price increases and good capacity utilisation. Operating profit improved to SEK 189 million, as against SEK 144 million in the same quarter last year."

    *For further information contact: *
    Roland Kasper, CEO, + 46 73 094 40 13, +46 222 440 13
    Anders Ulff, CFO, + 46 70 577 40 09, +46 222 440 09

    Systemair AB, SE-739 30 Skinnskatteberg, Sweden, +46 222 440 00, www.systemair.com

    Note: The information here is that which Systemair AB is obliged to make public under the EU's market abuse regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08:00 (CET) on December 5, 2018.* *

    * ** *
    *Systemair in brief*
    Systemair is a leading ventilation company with operations in 50 countries in Europe, North- and South America, the Middle East, Asia and Africa. The Company had sales of SEK 7.3 billion in financial year 2017/18 and currently employs about 5,500 people. Systemair has reported an operating profit every year since 1974, when the Company was founded. During the past 10 years, the Company's growth rate has averaged about 9 percent. 
    Systemair has well-established operations in growth markets. The Group's products are marketed under the Systemair, Frico, Fantech and Menerga brands. Systemair shares have been quoted on the Mid Cap List of the OMX Nordic Exchange in Stockholm since October 2007. The Group comprises about 70 companies.

    *Attachment*

    · Interim Report Systemair 2018_19 Q2-ENG.pdf Reported by GlobeNewswire 9 minutes ago.

    0 0

    *Elis continues its growth in Spain
    with the acquisition of **Lavanderias Triton*

    *Saint-Cloud, December 5, 2018* - Elis, an international multi-service provider, offering textile, hygiene and facility services solutions across Europe and Latin America, continues its acquisition strategy in its key markets and announces the closing of the acquisition of 100% of Lavanderias Triton, S.L in Spain.

    The Lavanderias Triton, S.L plant, located in the Madrid area is specialized in Flat linen operations and the vast majority of its customers operate in the Hospitality business. The company also serves the cities of Barcelona, Malaga, Elche and Segovia through partners.
    Lavanderias Triton, S.L is a family business that generated revenues of c. 8 million euros in 2017. The acquisition, which further expands the existing Elis network in Spain, will deliver synergies and allow Elis to to address a broader range of customers.

    Commenting on this announcement, *Xavier Martiré, CEO of Elis*, declared:

    "The acquisition of Lavanderias Triton enables Elis to continue the development of its network in Spain. The rapid integration of this family company will contribute to the continuation of Elis' profitable growth."

    *Contact*

    *Nicolas Buron
    *Investor Relations Director - Phone: +33 1 75 49 98 30 - nicolas.buron@elis.com

    *Audrey Bourgeois
    *Investor Relations - Phone: +33 1 75 49 96 25 - audrey.bourgeois@elis.com

    *Attachment*

    · Elis is growing in Spain with the acquisition of Lavanderias Triton.pdf Reported by GlobeNewswire 9 minutes ago.

    0 0

    *PRESS RELEASE*

    *5 December 2018*

    *WENTWORTH RESOURCES PLC*
    *("Wentworth" or the "Company")*

    *Long Term Incentive Plan ("LTIP") Awards*

    Wentworth, the Oslo Stock Exchange (OSE:WEN) and AIM (AIM:WEN) listed independent, East Africa-focused oil & gas company, is pleased to make the following announcement.

    On 3 December 2018, the Remuneration Committee of the Company, which consists solely of Non-Executive Directors, made an award under the Long Term Incentive Plan ("LTIP") which was approved by shareholders at the 2018 Annual General Meeting on 27 June 2018.

    Name Role LTIP award Vesting date Total options following the Grant
    Eskil Jersing Chief Executive Officer 2,670,226 2 December 2021 2,670,226
    Katherine Roe Chief Financial Officer 890,075 2 December 2021 890,075

    The awards are subject to a three-year performance period (the "Performance Period") followed by a two-year holding period. The awards are further subject to claw back and malus provisions.

    The performance condition for the awards is share price growth over the Performance Period, with 25% of the award vesting if the Company's share price at the end of the Performance Period has increased by an 8% compounded annual growth rate, and 100% of the award vesting if the share price has increased by a 16% compound annual growth rate. Should the share price increase between 8% and 16%, awards will vest on a linear sliding scale between 25% and 100%.

    -Ends-

    *Enquiries: *
    *Wentworth* Bob McBean,
    Executive Chairman

     

    Eskil Jersing,
    Chief Executive Officer

     

    Katherine Roe,
    Chief Financial Officer rpm@wentworthresources.com
    eskil.jersing@wentworthresources.com
    +44 7717 847623

     

    katherine.roe@wentworthresources.com
    +44 7841 087 230
    * *    
    *Stifel Nicolaus Europe Limited* *AIM Nominated Adviser and Broker (UK)*
    Callum Stewart
    Ashton Clanfield
    Simon Mensley +44 (0) 20 7710 7600
    * * * *  
    *Peel Hunt LLP* *Broker (UK)*
    Richard Crichton
    Ross Allister +44 (0) 20 7418 8900
    * * * *  
    *Vigo* *Investor Relations Adviser (UK)*
    Patrick d'Ancona
    Chris McMahon +44 (0) 20 7930 0230

    *About Wentworth Resources*

    Wentworth Resources is a publicly traded (OSE: WEN, AIM: WEN), independent oil & gas company with natural gas production; exploration and appraisal opportunities, all in the Rovuma Delta Basin of coastal southern Tanzania and northern Mozambique.

    *Inside Information*

    The information contained within this announcement is deemed by Wentworth to constitute inside information as stipulated under the Market Abuse Regulation (EU) no. 596/2014 ("MAR"). On the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

    *Cautionary note regarding forward-looking statements*

    This press release may contain certain forward-looking information. The words "expect", "anticipate", believe", "estimate", "may", "will", "should", "intend", "forecast", "plan", and similar expressions are used to identify forward-looking information.

    The forward-looking statements contained in this press release are based on management's beliefs, estimates and opinions on the date the statements are made in light of management's experience, current conditions and expected future development in the areas in which Wentworth is currently active and other factors management believes are appropriate in the circumstances. Wentworth undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless required by applicable law.

    Readers are cautioned not to place undue reliance on forward-looking information. By their nature, forward-looking statements are subject to numerous assumptions, risks and uncertainties that contribute to the possibility that the predicted outcome will not occur, including some of which are beyond Wentworth's control. These assumptions and risks include, but are not limited to: the risks associated with the oil and gas industry in general such as operational risks in exploration, development and production, delays or changes in plans with respect to exploration or development projects or capital expenditures, the imprecision of resource and reserve estimates, assumptions regarding the timing and costs relating to production and development as well as the availability and price of labour and equipment, volatility of and assumptions regarding commodity prices and exchange rates, marketing and transportation risks, environmental risks, competition, the ability to access sufficient capital from internal and external sources and changes in applicable law. Additionally, there are economic, political, social and other risks inherent in carrying on business in Tanzania and Mozambique. There can be no assurance that forward-looking statements will prove to be accurate as actual results and future events could vary or differ materially from those anticipated in such statements. See Wentworth's Management's Discussion and Analysis for the year ended December 31, 2017, available on Wentworth's website, for further description of the risks and uncertainties associated with Wentworth's business.

    *Notice *

    Neither the Oslo Stock Exchange nor the AIM Market of the London Stock Exchange has reviewed this press release and neither accepts responsibility for the adequacy or accuracy of this press release.

    This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

    *Attachment*

    · 181205 Press Release.pdf Reported by GlobeNewswire 9 minutes ago.

    0 0

    Dublin, Dec. 05, 2018 (GLOBE NEWSWIRE) -- The "Global Consumer Electronics B2C E-Commerce Market 2018" report has been added to *ResearchAndMarkets.com's* offering.China and the USA lead in online purchase of consumer electronics

    Global B2C E-Commerce of consumer electronics is predicted to maintain a compound annual growth rate in the single-digits between 2018 and 2023

    Continued growth is expected due to the increasing number of Internet connections, tech-savvy consumers and growing interest to the new electronics products and trends. One more important driving factor is an increase in the level of customers' trust in buying high-value products on the Internet, which results from offering a wider range of payment options and by improving delivery conditions.

    The largest value of online retail consumer electronics sales is generated by Asia and North America, as two regions that are the main producers and consumers of consumer electronics product worldwide, as the report reveals. China is the largest online retail consumer electronics market globally and is predicted to remain the leader in sales for at least the next 5 years.Consumers in China prefer to shop for electronic products from multichannel retailers, such as Guomei and Suning, and also from pure online retailers, like JD.com. B2C E-Commerce sales volume in the USA is the second largest in the world. The category Computer & Consumer Electronics is forecasted to generate the highest online retail sales in the country by the end of 2018. U.S. based bestbuy.com was the leading electronics retailer globally in term of website visits, as of October 2018.

    *Questions Answered in this Report*

    · What is the size of the online consumer electronics market and what are the predictions for 2023?
    · Which countries are leading in terms of online consumer electronics sales?
    · Which online consumer electronics trends are prevailing worldwide?
    · How is the online retail market of consumer electronics evolving in 30+ countries across all global regions?
    · Who are the major players on the B2C E-Commerce electronics market?

    *Key Topics Covered:*1. Management Summary

    2. Global Developments3. Asia-Pacific4. North America

    5. Europe

    6. Middle East

    7. Latin America

    * Companies Mentioned *· Advice Electronics Ltd
    · Alza.cz a.s.
    · Amazon.com Inc
    · Americanas.com SA
    · Apple Inc
    · Argos Ltd
    · Best Buy Co Inc.
    · Best Buy Co. Inc
    · awok.com
    · Bilka Bilgi Kaynak Ve Iletisim San.Ve Tic. A.S
    · BuscaPe.com Inc
    · CITILINK
    · Coolblue B.V.
    · DNS OOO
    · Darty plc
    · Digitec Galaxus AG
    · Directd Retail & Wholesale Sdn Bhd
    · Dixons Carphone plc
    · Dustin AB
    · eBay Inc
    · EURO-net Sp. z o.o.
    · FNAC SA
    · Fravega S.A.C.I. e I.
    · Gigantti Oy Ab
    · JB Hi-Fi Ltd
    · JD.com Inc
    · JIB Co. Ltd.
    · Lazada Group SA
    · M.Video Trade OOO
    · Media Markt Ag
    · Newegg Inc
    · notebooksbilliger.de AG
    · Rozetka. Ua Ltd
    · Samsung Electronics Co. Ltd.
    · Sony Mobile Communications Inc.
    · Submarino S.A
    · Suning.com Co. Ltd.
    · thegioididong.com
    · Walmart Inc
    · Xiaomi Inc
    · Yodobashi Camera Co. Ltd.

    For more information about this report visit https://www.researchandmarkets.com/research/qflzhp/global_consumer?w=12

    Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

    CONTACT:
    CONTACT: ResearchAndMarkets.com
    Laura Wood, Senior Press Manager
    press@researchandmarkets.com
    For E.S.T Office Hours Call 1-917-300-0470
    For U.S./CAN Toll Free Call 1-800-526-8630
    For GMT Office Hours Call +353-1-416-8900
    Related Topics: E-Business, Consumer Electronics Reported by GlobeNewswire 3 hours ago.

    0 0

    Dublin, Dec. 05, 2018 (GLOBE NEWSWIRE) -- The "Chemotherapy-Induced Peripheral Neuropathy (CIPN) - Market Insights, Epidemiology and Market Forecast" drug pipelines has been added to *ResearchAndMarkets.com's* offering.The Chemotherapy-Induced Peripheral Neuropathy (CIPN) - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of CIPN in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), Japan and China.

    The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Chemotherapy-Induced Peripheral Neuropathy from 2016 to 2027 segmented by eight major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

    *Chemotherapy-Induced Peripheral Neuropathy - Disease Understanding and Treatment Algorithm*

    Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent, dose-dependent complication of anticancer drugs, including platinums, taxanes, epothilones, vinca alkaloids, and newer agents, such as bortezomib. It not only leads to dose reduction or discontinuation of treatment but also decreases the quality of life of cancer survivors.

    With the exception of paclitaxel and oxaliplatin, which cause an acute neuropathy that emerges either during or shortly after infusion, the onset of CIPN is usually delayed and appears to depend on the total cumulative dose. Clinically, CIPN presents as deficits in sensory, motor, and autonomic function which develop in a compound-specific manner.

    The Chemotherapy-Induced Peripheral Neuropathy (CIPN) market report gives the thorough understanding of the CIPN by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for CIPN in the US, Europe, Japan and China.

    *Chemotherapy-Induced Peripheral Neuropathy Epidemiology*

    The Chemotherapy-Induced Peripheral Neuropathy epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 8 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.

    This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

    The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Incident Population of CIPN, Severity Specific Incident Population of CIPN and Incident Population of CIPN by Chemotherapeutic Agents] scenario of Chemotherapy-Induced Peripheral Neuropathy in the G8 countries covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), Japan and China from 2016-2027.

    According to the publisher, incident population of CIPN in the G8 countries is expected to increase at a CAGR of 0.35% for the study period i.e. 2016-2027. The publisher estimates show higher incidence of CIPN in China with 1,542,149 cases in 2016, due to the higher incidence of cancer than US, EU5 and Japan.

    Among the European countries, Germany had the highest incident population of CIPN, followed by the United Kingdom in 2016. On the other hand, Spain had the lowest incident population of nearly 80,000 in 2016. According to the report, majority of the CIPN cases is caused by the platinum-based chemotherapeutic agents such as oxaliplatin and cisplatin, followed by taxane agents.

    Furthermore, assessments show that in terms of severity, the majority of the patients have been diagnosed with moderate and severe forms of CIPN, while mild CIPN cases were also diagnosed. In 2016, incident cases of mild, moderate and severe CIPN in the US varied in the range 100,000 to 300,000. This trend is expected to be followed during the forecast period [2018-2027].

    *Chemotherapy-Induced Peripheral Neuropathy Drug Chapters*

    This segment of the Chemotherapy-Induced Peripheral Neuropathy (CIPN) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

    The market size of CIPN depends entirely on the type of nerve damage, symptoms, and location. Currently, there is no approved therapy for the treatment of CIPN. The current therapeutic landscape of CIPN worldwide is dependent on off-label therapies, used to reduce the symptoms in CIPN patients.

    Guidelines for the prevention and management of CIPN in survivors of adult cancers, have reported pharmacologic treatment of neuropathic pain developed with a consensus that alpha-2-delta antagonist (anticonvulsants), serotonin-norepinephrine re-uptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), opioids, and topical analgesics are good treatment options for neuropathic pain.

    Detailed chapters of upcoming therapies such as SP-04 (PledOx; Solasia), Tetrodotoxin (TTX; WEX Pharmaceuticals) and E-52862 (Esteve), which are expected to launch during the forecast period [2018-2027] have also been covered in the report.

    *Chemotherapy-Induced Peripheral Neuropathy Market Outlook*

    The Chemotherapy-Induced Peripheral Neuropathy (CIPN) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

    This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

    The market size of Chemotherapy Induced Peripheral Neuropathy (CIPN) in the G8 Countries is expected to increase at a CAGR of 2.94% for the study period (2016-2027). Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the incident population of CIPN.

    Among the different classes of therapies which are currently prescribed to patients with CIPN, opioid analgesics is the most prescribed one that led to highest market size among other classes. China accounts for the highest market size of CIPN in comparison to the United States, the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

    *Chemotherapy-Induced Peripheral Neuropathy Drugs Uptake*

    This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

    This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

    Many companies are aggressively working towards the development of targeted therapies for CIPN such as PledOx/Solasia, WEX Pharmaceuticals, Asahi Kasei, MediciNova, Achelios Therapeutics, Esteve, ChromaDex, Apollo Endosurgery (Lpath), Hoffmann-La Roche, Midatech/DARA, Lee's Pharmaceutical Limited, Novartis, Relief Therapeutics and others. Of the aforementioned pharmaceutical companies, targeted products by Solasia (SP-04), WEX Pharmaceuticals (Tetrodotoxin) and Esteve (E-52862) are expected to be launched during the forecast period [2018-2027].

    It has been assessed that SP-04 holds the highest expectations of analysts. Despite the launch E-52862 (Esteve) later than Tetrodotoxin (TTX; WEX Pharmaceuticals), E-52862 is predicted to create comparatively greater impact on the market size of CIPN. This may be attributed to the target-specific mechanism of E-52862 for CIPN, while Tetrodotoxin will be launched by WEX Pharmaceuticals, for overall neuropathic pain.

    *Chemotherapy-Induced Peripheral Neuropathy Report Insights*

    · Patient Population
    · Therapeutic Approaches
    · Pipeline Analysis
    · Market Size and Trends
    · Market Opportunities
    · Impact of upcoming Therapies

    *Chemotherapy-Induced Peripheral Neuropathy Report Key Strengths*

    · 10 Years Forecast
    · G8 Coverage
    · Epidemiology Segmentation
    · Key Cross Competition
    · Market Size by Therapies
    · Drugs Uptake

    *Chemotherapy-Induced Peripheral Neuropathy Report Assessment*

    · Pipeline Product Profiles
    · Key Products and Key Players
    · Market Drivers and Barriers

    *Key Benefits*

    · This report will help to develop Business Strategies by understanding the trends shaping and driving Chemotherapy-Induced Peripheral Neuropathy market
    · Organize sales and marketing efforts by identifying the best opportunities for Chemotherapy-Induced Peripheral Neuropathy market
    · To understand the future market competition in the Chemotherapy-Induced Peripheral Neuropathy market.

    For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/r8ckr4/chemotherapyinduc?w=12

    Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

    CONTACT:
    CONTACT: ResearchAndMarkets.com
    Laura Wood, Senior Press Manager
    press@researchandmarkets.com
    For E.S.T Office Hours Call 1-917-300-0470
    For U.S./CAN Toll Free Call 1-800-526-8630
    For GMT Office Hours Call +353-1-416-8900
    Related Topics: Central Nervous System Drugs Reported by GlobeNewswire 3 hours ago.

    0 0

    Dublin, Dec. 05, 2018 (GLOBE NEWSWIRE) -- The "The Global Caprolactam Market" report has been added to *ResearchAndMarkets.com's* offering.
    According to a recently conducted research about the global caprolactam market, as an overall, it is projected to reach approximately 6,564 thousand tons by the end of 2023, increasing at a CAGR of around 3% per year in the period 2017-2023.

    The report focuses on both product and regional breakdown, offering a larger perspective on the market dynamics. Although caprolactam is predominantly used for the manufacture of synthetic fibers, the analysis considers the application of caprolactam across various industries.

    In particular, the largest share of caprolactam consumption is for the production of polyamide fibers, which accounted for around 55% of the total in volume terms. Meanwhile, the chemical's application for PAM resins has been growing with the highest rate of about 5.58% per year.

    Regionally, the largest global caprolactam market was North East Asia, which accounted for about 50% of the total in volume terms. In comparison, Africa was the smallest global caprolactam market during the analyzed period and is expected to remain such in the medium term.

    During the last several years, the development of the automobile industry is one of the major factors, driving the global caprolactam market. This is due to the variety of applications of nylon 6 in different automotive parts such as door handles, air bag containers, radiator grilles, relay boxes, air intake manifold and engine covers, among others.

    Furthermore, automakers are focusing on light weighting of vehicles in order to improve fuel efficiency and performance. Therefore, metallic parts of automobile are being rapidly replaced by nylon 6 due to high temperature and chemical resistance.

    In addition, innovation in the field of electronics along with increasing consumption of smart phones, tablets, laptops and TVs has resulted in driving demand for engineering plastics, subsequently driving the growth of the global caprolactam market.

    The growing demand for convenience food across the globe is also a major contributor for the demand growth for specialty films for packing. Since nylon 6 is a key constituent in specialty films, the latter is driving the global caprolactam market.

    In recent years on the global scene many large market players closed their capacities, owing to the capacity surged in Asia over the past few years. Another fact, influencing the caprolactam market is the recent Chinese policy decision.

    In October 2017, the China's Ministry of Commerce (MOC) announced that it will extend anti-dumping duties on imports of caprolactam from the EU and the US for another five years.

    The demand for caprolactam in North America was estimated to be more in resins as compared to fibers over the last two years. It was supported by stringent government regulations, increasing pressure for lightweight and durable polyamide 6, as well as the need for improving the standard of processing and manufacturing end products.*Key Topics Covered*

    *1. Introduction*
    1.1. Report description
    1.2. Research methodology

    *2. Executive summary*

    *3. Characteristics of caprolactam *

    *4. State of the global demographics and economy*
    4.1. Characteristics of the global demographics in 2013-2017
    4.2. Characteristics of the global economy in 2013-2017
    4.3. Forecast for the development of the global economy in the medium term

    *5. Overview and analysis of the global caprolactam market*
    5.1. Volume and dynamics of the global caprolactam market in 2013-2017 and forecast for 2018-2023
    5.2. Structure of the global caprolactam market by main regions in 2013-2017 and forecast for 2018-2023
    5.3. Structure of the caprolactam market in Africa by countries in 2013-2017 and forecast for 2018-2023
    5.4. Structure of the caprolactam market in Asia and Pacific by countries in 2013-2017 and forecast for 2018-2023
    5.5. Structure of the caprolactam market in the CIS countries by countries in 2013-2017 and forecast for 2018-2023
    5.6. Structure of the caprolactam market in Europe by countries in 2013-2017 and forecast for 2018-2023
    5.7. Structure of the caprolactam market in the Middle East by countries in 2013-2017 and forecast for 2018-2023
    5.8. Structure of the caprolactam market in North America by countries in 2013-2017 and forecast for 2018-2023
    5.9. Structure of the caprolactam market in North East Asia by countries in 2013-2017 and forecast for 2018-2023
    5.10. Structure of the caprolactam market in South and Central America by countries in 2013-2017 and forecast for 2018-2023
    5.11. Structure of the global caprolactam market by application/main product groups in 2013-2017 and forecast for its development in 2018-2023
    5.12. Key recent trends on the global caprolactam market
    5.13. Key drivers and restraints for the market development in the medium term

    *6. Overview and analysis of the global production of caprolactam*
    6.1. Volume, distribution and dynamics of the installed capacities for the global production of caprolactam broken down by regions in 2013-2017 and forecast for their development in 2018-2023
    6.2. Volume and dynamics of the average annual utilization rates used for the production of caprolactam globally, broken down by regions, in 2013-2017 and forecast for their development in 2018-2023
    6.3. Volume and dynamics of the global production of caprolactam in 2013-2017 and forecast for 2018-2023
    6.4. Structure of the global production of caprolactam in 2013-2017 by main regions and forecast for 2018-2023
    6.5. Structure of the caprolactam production in Africa by countries in 2013-2017 and forecast for 2018-2023
    6.6. Structure of the caprolactam production in Asia and Pacific by countries in 2013-2017 and forecast for 2018-2023
    6.7. Structure of the caprolactam production in the CIS countries by countries in 2013-2017 and forecast for 2018-2023
    6.8. Structure of the caprolactam production in Europe by countries in 2013-2017 and forecast for 2018-2023
    6.9. Structure of the caprolactam production in the Middle East by countries in 2013-2017 and forecast for 2018-2023
    6.10. Structure of the caprolactam production in North America by countries in 2013-2017 and forecast for 2018-2023
    6.11. Structure of the caprolactam production in North East Asia by countries in 2013-2017 and forecast for 2018-2023
    6.12. Structure of the caprolactam production in South and Central America by countries in 2013-2017 and forecast for 2018-2023
    6.13. Characteristics of the main producers of caprolactam globally along with their exact installed capacities and used production techniques

    *7. Characteristics and analysis of the global prices of caprolactam*
    7.1. Value chain analysis
    7.2. Structure of price formation
    7.3. Characteristics of the global prices of caprolactam in 2013-2017 and forecast for 2018-2023
    7.4. Characteristics of the regional prices of caprolactam in 2013-2017 and forecast for 2018-2023

    *8. Overview and analysis of the global imports of caprolactam*
    8.1. Volume, value and dynamics of the global imports of caprolactam in 2013-2017
    8.2. Structure of the global imports of caprolactam by main regions in 2013-2017
    8.3. Average prices of the caprolactam, imported globally in 2013-2017

    *9. Overview and analysis of the global exports of caprolactam*
    9.1. Volume, value and dynamics of the global exports of caprolactam in 2013-2017
    9.2. Structure of the global exports of caprolactam by main regions in 2013-2017
    9.3. Average prices of the global exports of caprolactam in 2013-2017

    *10. Balance between supply and demand on the global caprolactam market*
    10.1. Balance between supply and demand on the global caprolactam market in 2013-2017 and forecast for 2018-2023
    10.2. Balance between supply and demand on the global caprolactam market by main regions in 2013-2017 and forecast for 2018-2023

    * Companies Mentioned *· BASF
    · Lanxess
    · Domo Caproleuna
    · Grupa Azoty
    · Ube Industries
    · Grodno Azot
    · Azot Kemerovo
    · Kuibyshevazot
    · Shchekinoazot
    · Azot Cherkassy
    · Advansix
    · Fibrant
    · Abel Chemical
    · China Risun Coal Chemicals Group
    · Fibrant
    · Fujian Eversun Holding
    · Fujian Jinjiang Pc Comp. Lim.
    · Fujian Shenyuan New Materials
    · Fujian Tianchen Yaolong New Mat.
    · Hengshen Technology
    · Hubei Sanning Chem Co
    · Jiangsu Haili Chemical
    · Juhua Group Corp.
    · Luxi Chemical Group
    · Shandong Fangming Pc
    · Shandong Haili Chemical
    · Shanxi Jintaoyuan
    · Shanxi Lanhua Sci-Tech Venture
    · Shanxi Lubao Group Coking
    · Shenma Group
    · Sinopec Baling Pc
    · Sinopec Shijiazhuang Rf Ch
    · Taiyuan Chem. Ind.
    · Zhejiang Baling Hengyi
    · Sumitomo Chemical
    · Toray Industries
    · Ube Industries
    · Capro Corp.
    · Fert. and Chem. Travancore
    · Gujarat State Fertilizer
    · Ube Chemicals (Asia)
    · Monomeros Col/Venez

    For more information about this report visit https://www.researchandmarkets.com/research/6q2hrv/global?w=12

    CONTACT:
    CONTACT: ResearchAndMarkets.com
    Laura Wood, Senior Press Manager
    press@researchandmarkets.com
    For E.S.T Office Hours Call 1-917-300-0470
    For U.S./CAN Toll Free Call 1-800-526-8630
    For GMT Office Hours Call +353-1-416-8900
    Related Topics: Petrochemicals Reported by GlobeNewswire 2 hours ago.

older | 1 | .... | 1565 | 1566 | (Page 1567) | 1568 | 1569 | .... | 1652 | newer